RBE细胞系

RBE/RBE细胞系/RBE细胞株/RBE人胆管癌细胞

Cell line name RBE

Accession CVCL_4896

Resource Identification Initiative To cite this cell line use: RBE (RRID:CVCL_4896)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: JFCR45 cancer cell line panel.

Population: Japanese.

Doubling time: 45 hours (PubMed=9358283).

Omics: Deep exome analysis.

Omics: Transcriptome analysis by microarray.

Misspelling: RBA; CelloPub=CLPUB00275.

Derived from site: In situ; Liver; UBERON=UBERON_0002107.

Sequence variations

Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Ser (c.394C>A); ClinVar=VCV000375893; Zygosity=Unspecified (PubMed=27231123; DepMap=ACH-001856).

Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (DepMap=ACH-001856).

Disease Intrahepatic cholangiocarcinoma (NCIt: C35417)

Cholangiocarcinoma (ORDO: Orphanet_70567)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_A9CU (RBE-Luc2-tdT)

Sex of cell Female

Age at sampling 64Y

Category Cancer cell line

STR profile Source(s): CCRID; DepMap=ACH-001856; RCB=RCB1292

 

Markers:

Amelogenin X

CSF1PO 12

D2S1338 17,24

D3S1358 14,15

D5S818 11,12

D7S820 8,11

D8S1179 13,14

D13S317 9

D16S539 10,11

D18S51 13,15

D19S433 14,15.2

D21S11 29

FGA 19,24

Penta D 12

Penta E 18

TH01 6

TPOX 8

vWA 20

 

Run an STR similarity search on this cell line

Publications

PubMed=9358283; DOI=10.1007/s11626-997-0125-z

Enjoji M., Sakai H., Nawata H., Kajiyama K., Tsuneyoshi M.

Sarcomatous and adenocarcinoma cell lines from the same nodule of cholangiocarcinoma.

In Vitro Cell. Dev. Biol. Anim. 33:681-683(1997)

 

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

 

CLPUB00275

Zach S., Birgin E., Ruckert F.

Primary cholangiocellular carcinoma cell lines.

J. Stem Cell Res. Transplant. 2:1013-1013(2015)

 

PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737

Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H., El-Bardeesy N.

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.

Cancer Discov. 6:727-739(2016)

 

PubMed=31077409; DOI=10.1002/hep.30704

Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.

Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.

Hepatology 70:1614-1630(2019)

 

PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155

Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.

Development and characterization of human primary cholangiocarcinoma cell lines.

Am. J. Pathol. 192:1200-1217(2022)